ICVX Stock Recent News

Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences:

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The company's Q4 update made investors feel a little better after receiving disappointing news last week.